^99Tc^m-甲氧基异丁基异腈SPECT预测肺癌多药耐药及化疗疗效  

Single photon emission computed tomography imaging using ^99Tc^m-methoxyisobutylisonitrile predict the multi-drug resistance and chemotherapy efficacy of lung cancer

作　　者：张一秋[1] 石洪成[1] 

机构地区：[1]复旦大学附属中山医院核医学科,上海200032

出　　处：《国际放射医学核医学杂志》2008年第6期329-332,共4页International Journal of Radiation Medicine and Nuclear Medicine

摘　　要：化疗作为肺癌特别是非小细胞肺癌综合治疗的主要手段之一。肺癌耐药尤其是多药耐药成为化疗失败的重要原因。早期发现多药耐药，选择合适的化疗方案，对于肺癌患者至关重要。肺癌的多药耐药与多药耐药相关蛋白（MRP）在肺癌中表达相关，某些亲脂性抗癌化疗药物和^99Tc^m-甲氧基异丁基异腈（^99Tc^m-MIBI）可能同为某些MRP的底物，它们在肿瘤细胞中的滞留与MRP的表达相关。因而行无创性的肺^99Tc^m-MIBISPECT，在化疗前预测体内MRP的表达或在化疗过程中监测MRP表达的变化，有助于预测肺癌多药耐药及化疗疗效。Chemotherapy is one of the main comprehensive treatments for lung cancer, especially for non-small cell lung cancer （NSCIC） Multi-drug resistance of lung cancer plays an important role in the failure of chemotherapy. Early detection of multi-drug resistance （MDR） is essential for choosing a suitable chemotherapy regimen for the patients of lung cancer. In recent years lots of literature reports that MDR of lung cancer is related to many kinds of multi-drug resistance protein （MRP） expression in lung cancer. Some lipophilic chemotherapy drugs and ^99Tc^m-methoxyisobutylisonitrile（^99Tc^m-MIBI） may be the same substrate for some MRP. These MRP can transport them out of the tumor cells, then the chemotherapy is invalid or nonradioactive concentration. The retention of ^99Tc^m-MIBI in tumor cells is correlated with the expression of MRP, thus the prediction of the MRP expression before chemotherapy or monitoring MRP expression changes in the process of chemotherapy by using the noninvasive ^99Tc^m-MIBI single photon emission computed tomography imaging is helpful to predict the MDR and chemotherapy efficacy of lung cancer.

关 键 词：^99Tc^m-氧基异丁基异腈 体层摄影术 发射型计算机 单光子 肺肿瘤 抗药性 多药 

分 类 号：R734[医药卫生—肿瘤]